Apart from CD44+CD24−/low and ALDH1+, various markers have been reported to identify and isolate BCSCs in human and mouse breast cancer, which supports further research on BCSCs and provides a premise for clinical BCSC targeting (Table 1). This evidence concerns the gene CD24 and breast cancer.